Monoclonal Antibody of 100 μg targeting PCLP1 for FCM.
| Product Specifications | |
| Application | FC |
| Reactivity | Human |
| Clonality | Monoclonal IgG2a |
| Host | Mouse |
| Immunogen | CHO cells expressing the (length) human Podacalyxin/PCLP1 |
| Formulation | 1 mg/mL in PBS/50% glycerol, pH 7.2 |
| Storage | |
| Documents & Links for Anti-Podocalyxin (PCLP1) (Human) mAb (Clone: 53D11) | |
| Datasheet | Anti-Podocalyxin (PCLP1) (Human) mAb (Clone: 53D11) Datasheet |
| Documents & Links for Anti-Podocalyxin (PCLP1) (Human) mAb (Clone: 53D11) | |
| Datasheet | Anti-Podocalyxin (PCLP1) (Human) mAb (Clone: 53D11) Datasheet |
| Citations for Anti-Podocalyxin (PCLP1) (Human) mAb (Clone: 53D11) – 1 Found |
| Itai, Shunsuke; Ohishi, Tomokazu; Kaneko, Mika K; Yamada, Shinji; Abe, Shinji; Nakamura, Takuro; Yanaka, Miyuki; Chang, Yao-Wen; Ohba, Shun-Ichi; Nishioka, Yasuhiko; Kawada, Manabu; Harada, Hiroyuki; Kato, Yukinari. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget. 2018;9(32):22480-22497. PubMed - Comments: Used in: FCM |
